(Reuters Health) – About one in four U.S. oncologists rarely or never discusses the price of genomic testing with their cancer patients, even though cost is important for informed decision-making, survey results suggest. “Cancer patients and their caregivers may be limited in their ability to work during treatment. This can reduce income, and in some cases, may affect access to employer-sponsored health insurance coverage,” said lead study author Robin Yabroff, senior scientific director of the Surveillance and Health Services Research Program at the American Cancer Society in Atlanta, Georgia. Hundreds of molecularly-targeted cancer therapies are available and thousands are in



This content is restricted to site members. If you are an existing user, please log in. New users may register too.